Leerink Partners Initiates Scribe Therapeutics at Outperform With $37 Price Target
Leerink Partners has initiated coverage on Scribe Therapeutics with an "Outperform" rating and set a price target of $37. This news follows similar positive initiations from Guggenheim and Wells Fargo, signaling growing analyst confidence in the biotechnology company. Scribe Therapeutics focuses on engineering in …